NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Entry into a Material Definitive AgreementItem 3.02. Entry into a Material Definitive Agreement.
Amendment to Facility Agreement
On November5, 2018, Neos Therapeutics,Inc. (the “Company”), Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. (together, the “Lenders”) entered into a Second Amendment (the “Amendment”) to the Company’s existing Facility Agreement, (as amended, the “Agreement”) with the Lenders. The Company borrowed a principal amount of $60.0 million (the “Borrowings”) to the Agreement in May 2016.
to the terms of the Amendment, the Company has agreed to pay $7.5 million in Borrowings upon completion of a proposed public offering (the “Offering”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The remaining $52.5 million of Borrowings is due as follows: $7.5 million on May11, 2019, $15.0 million on May11, 2020 (the “2020 Principal Payment”), $15.0 million on May11, 2021 and $15.0 million on May11, 2022; provided, that the 2020 Principal Payment due date shall be extended to May11, 2021 or May11, 2022 subject to achievement of certain revenue milestones set forth in the Amendment. If all or any of the Borrowings are prepaid or required to be prepaid under the Agreement prior to December31, 2021, then the Company shall pay, in addition to such prepayment and accrued interest thereon, a prepayment premium equal to6.25% of the amount of principal prepaid. Additionally, the Company shall pay all interest which, absent such prepayment, would have accrued on the principal prepaid through May11, 2020 in connection with a prepayment due as a result of a change of control of the Company or through December31, 2020 in connection with any other prepayment. If such prepayment occurs after December31, 2021 then no prepayment premium is due.
to the Amendment, upon the effectiveness thereof, the Company will amend and restate its outstanding notes under the Agreement in the form of senior secured convertible notes (the “Convertible Notes”). Under the terms of the Amendment and the Convertible Notes, beginning on or about May11, 2019, the Company will have the right to pay Borrowings and future interest in shares of Common Stock not to exceed 2,135,625 shares in the aggregate. Additionally, the Lenders will have the right to convert the remaining Borrowings into shares of Common Stock not to exceed 3,796,668 shares in the aggregate (collectively, the “Conversion Shares”); provided, that the Lenders may only convert up to 50% of the remaining Borrowings on or before November 5, 2019. The Lenders’ per share conversion price will be 95% (subject to adjustment as provided in the Convertible Notes) of the greater of (A) the average of the volume weighted average prices per share of the Common Stock on the NASDAQ Global Market for the three trading day period immediately preceding such conversion, and (B)$10.00 (subject to adjustment as provided in the Convertible Notes). The Lenders’ right to convert the remaining Borrowings into shares of Common Stock is memorialized in the form of Convertible Notes to be issued to the Lenders upon effectiveness of the Amendment.
The effectiveness of the Amendment is subject to the satisfaction or waiver of certain conditions set forth therein, including the completion of the Offering.
Registration Rights Agreement
In connection with theAmendmentand the issuance of theConvertibleNotes thereto, the Company entered into a Registration RightsAgreementwith the Lenders (the “Registration RightsAgreement”), to which the Company agreed to register for sale the Conversion Shares within a specified time period following the issuance of the ConvertibleNotes.
The Lenders beneficially own less than 5% of the capital stock of the Company as of December31, 2017, based on a Schedule13G filed with the Securities and Exchange Commission (the “SEC”) on February14, 2018.
The foregoing descriptions of the material terms of the Convertible Notes, the Amendment and the Registration Rights Agreement do not purport to be complete and are subject to, and are qualified in their entirety by, reference to the form of Convertible Note, the Amendment and the Registration Rights Agreement, copies of which are attached to this Current Report on Form8-K as Exhibit4.1, Exhibit10.1 and Exhibit10.2, respectively.
Item 3.02. Results of Operations and Financial Condition.
In connection with a proposed public offering of its Common Stock the Company intends to file a preliminary prospectus supplement to the base prospectus included in the Company’s shelf registration statement on FormS-3 (No.333-212809), filed with the SEC on August1, 2016 and declared effective by the SEC on August12, 2016. The